Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patientsPUBT·Jul 23 at 06:32 AMNVCT+1.15%002653-4.80%
China's Haisco Gets China’s Nod for Rare Blood Disorder DrugYicai·Jul 23 at 06:27 AM002653-4.80%NVCT+1.15%
02:08 ETHaisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNHprnewswire·Jul 23 at 01:10 AM002653-4.80%
Haisco and Nuvectis sign licensing deal for two drugsPharmaceutical Technology·Jun 24 at 03:10 AMNVCT+1.15%002653-4.80%
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement IndicationsUnusual Whales·Jun 23 at 08:20 AM002653-4.80%NVCT+1.15%
Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trendingbenzinga_article·Jun 23 at 01:30 AMNVCT+1.15%002653-4.80%
Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLArttnews·Jun 22 at 10:15 PMAZTR+3.06%FTH+0.17%
Nuvectis licenses ex-China rights to Haisco’s NXP100, NXP200 in deal worth up to USD 1.42 billionPUBT·Jun 22 at 06:30 AMNVCT+1.15%
Nuvectis Pharma shares are trading higher after the company announced a strategic portfolio expansion with Haisco Pharmaceutical Group. Also, HC Wainwright & Co raised its price target on the stock from $13 to $39.benzinga_article·Jun 22 at 12:38 PMNVCT+1.15%002653-4.80%
